2-hydroxyglutarate rides the cancer-immunity cycle

• Verfasst von: Foskolou, Iosifina [VerfasserIn]
• Verfasst von: Bunse, Lukas [VerfasserIn]
• Verfasst von: Van den Bossche, Jan [VerfasserIn]
• Titel: 2-hydroxyglutarate rides the cancer-immunity cycle
• Verf.angabe: Iosifina P Foskolou, Lukas Bunse, Jan Van den Bossche
• E-Jahr: 2023
• Jahr: October 2023
• Umfang: 7 S.
• Fussnoten: Online verfügbar: 27. Juli 2023 ; Gesehen am 19.10.2023
• Titel Quelle: Enthalten in: Current opinion in biotechnology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1990
• Jahr Quelle: 2023
• Band/Heft Quelle: 83(2023) vom: Aug., Artikel-ID 102976, Seite 1-7
• ISSN Quelle: 1879-0429
• DOI: doi:10.1016/j.copbio.2023.102976
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1866371673

Abstract

2-hydroxyglutarate (2HG) is a biproduct of the Krebs cycle, which exists in a D- and L- enantiomer and is structurally similar to α-ketoglutarate. Both 2HG enantiomers have been described to accumulate in diverse cancer and immune cells and can influence cell fate and function. While D-2HG was originally considered as an ‘oncometabolite’ that aberrantly builds up in certain cancers, it is becoming clear that it also physiologically accumulates in immune cells and regulates immune function. Conversely, L-2HG is considered as an ‘immunometabolite’ due to its induction and regulatory function in T cells, but it can also be induced in certain cancers. Here, the authors review the effects of both 2HG enantiomers on immune cells within the tumor microenvironment.